A recent study, combined hormone replacement therapy for menopause, continuous take, does not increase the risk of uterine cancer. Instead, it would seem protective.
1.The advantages of hormone replacement therapy
At the time of menopause, hormone replacement therapy based on estrogen is prescribed to combat the risks of estrogen deficiency (both short term on the symptoms of menopause such as hot flashes , on the long term aging the skin , arteries, etc..). Estrogens promote the proliferation of endometrial cells, it is recommended to associate with a progestin, which compensates this effect. Thus, the risk of uterine cancer is not increased with the treatment, called “combined” combining estrogen and progesterone. There are two types: continuous or discontinuous engagement (14 days per cycle).
A team of researchers studied the effects of continuous combined hormone therapy in postmenopausal women with a cancer of the endometrial (uterine lining) by compared to a control population. Women who received continuous treatment, compared to patients not following any treatment, have a risk of uterine cancer by 0.6. This risk is 0.4 compared to intermittent hormone therapy. Taking continuous hormone substitutive over several years does not increase the risk of endometrial cancer, rather it tends to decrease, showing that combined form (estrogen and progesterone) is continuous in the most advantageous. Continue reading “HORMONE REPLACEMENT THERAPY CONTINUOUSLY DECREASES THE RISK OF UTERINE CANCER”